Skip to main content
. 2023 Sep 19;13:15461. doi: 10.1038/s41598-023-42788-6

Figure 3.

Figure 3

The proportion of progression (newly diagnosed or worsened severity) in non-alcoholic fatty liver disease (NAFLD) after menopausal hormone therapy (MHT) according to estrogen dose (A) and type of progestogen (B). P value based on chi-square test.